Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CABA Cabaletta Bio Inc
- Stocks
- Healthcare
- NASDAQ: CABA
Price (delayed)
$2.21
Market cap
$112.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.54
Enterprise value
$9.11M
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative,
Highlights
CABA's debt has surged by 85% since the previous quarter
Cabaletta Bio's quick ratio has shrunk by 69% YoY and by 36% QoQ
Key stats
What are the main financial stats of CABA
Market
Valuations
Earnings
Shares outstanding
50.74M
Market cap
$112.14M
Enterprise value
$9.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$134.25M
Net income
-$126.76M
EBIT
-$125.72M
EBITDA
-$121.62M
Free cash flow
-$97.22M
Per share
Balance sheet
Liquidity
EPS
-$2.54
EPS diluted
-$2.54
Free cash flow per share
-$1.92
Book value per share
$2.4
Revenue per share
$0
TBVPS
$3.25
Total assets
$165.14M
Total liabilities
$43.59M
Debt
$28.79M
Equity
$121.55M
Working capital
$100.61M
Debt to equity
0.24
Current ratio
3.96
Quick ratio
3.88
Net debt/EBITDA
0.85
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-65.7%
Return on equity
-78.3%
Return on invested capital
-545.6%
Return on capital employed
-95.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CABA stock price
How has the Cabaletta Bio stock price performed over time
Intraday
1.38%
1 week
18.18%
1 month
64.93%
1 year
-77.77%
YTD
-2.64%
QTD
59.57%
Financial performance
How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$134.25M
Net income
-$126.76M
Gross margin
N/A
Net margin
N/A
CABA's net income has dropped by 65% year-on-year and by 9% since the previous quarter
The operating income has plunged by 57% YoY and by 7% from the previous quarter
Price vs fundamentals
How does CABA's price correlate with its fundamentals
Growth
What is Cabaletta Bio's growth rate over time
Valuation
What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
0.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is down by 48% YoY and by 9% QoQ
CABA's price to book (P/B) is 54% lower than its 5-year quarterly average of 2.0 and 16% lower than its last 4 quarters average of 1.1
The equity has contracted by 45% YoY and by 20% from the previous quarter
Efficiency
How efficient is Cabaletta Bio business performance
Cabaletta Bio's ROE has plunged by 102% YoY and by 26% from the previous quarter
Cabaletta Bio's return on assets has shrunk by 82% YoY and by 20% QoQ
The ROIC has contracted by 41% from the previous quarter
Dividends
What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CABA.
Financial health
How did Cabaletta Bio financials performed over time
Cabaletta Bio's total liabilities has soared by 133% YoY and by 33% from the previous quarter
The current ratio has plunged by 69% YoY and by 36% from the previous quarter
CABA's debt is 76% smaller than its equity
Cabaletta Bio's debt to equity has soared by 140% from the previous quarter
CABA's debt has surged by 85% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.